RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Priority Review (United States), Priority Review (China)

Structure/Sequence

Molecular FormulaC20H25ClN6O2S

InChIKeyUHYCLWAANUGUMN-SSEXGKCCSA-N

CAS Registry1423719-30-5

Clinical Trials associated with Nerandomilast

NCT07321860

/ Not yet recruitingPhase 2/3

Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Partial TGF-βR1 (ALK5) Inhibition With Galunisertib Combined With PDE4 Inhibition With Nerandomilast in GREM2-Positive ALS

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality. A growing body of translational and clinical evidence implicates neuroinflammation, reactive astrocytosis, and maladaptive TGF-β signaling as central contributors to disease progression. Elevated levels of Gremlin-2 (GREM2) have been identified as a marker of dysregulated TGF-β-linked astrocytic activity and fibrotic gene programs in some ALS patients, and preclinical data suggest that attenuating these pathways may mitigate glial toxicity and improve neuronal survival.
Galunisertib, a selective ATP-competitive TGF-β receptor type I (TGF-βR1/ALK5) inhibitor, has been developed to block SMAD2/3 phosphorylation and TGF-β-mediated transcriptional programs. Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades. Preclinical models show that PDE4 inhibition and TGF-β pathway blockade concurrently reduce maladaptive glial phenotypes and fibrotic mediators.
This study investigates the combination of galunisertib + nerandomilast in ALS patients with elevated GREM2, hypothesizing that dual targeting of TGF-β-mediated astrocytic reactivity and PDE4B-regulated inflammatory signaling will translate into slowing of disease progression and favorable pharmacodynamic effects on central biomarkers of neuroinflammation and neurodegeneration.

Start Date30 Jun 2026

Sponsor / Collaborator-

NCT07201922

/ Not yet recruitingPhase 3

A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis.
Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo.
Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months.
Doctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.

Start Date23 Jan 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT06241560

/ Not yet recruitingPhase 2

An Open-label, Single-group Trial to Evaluate the Effect of Pirfenidone on the Pharmacokinetics of a Single Oral Dose of BI 1015550

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another.
Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet.
Participants are in the study for a little over 1 month. During this time, they visit the study site 15 times. Two of the visits include overnight stays at the study site. The study staff also contacts the participants by phone. During the visits, the doctors collect information about participants' health and take blood samples from the participants. They compare the amount of pirfenidone and BI 1015550 in the blood. Doctors also regularly check participants' health and take note of any unwanted effects.

Start Date09 Jan 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Nerandomilast

100 Translational Medicine associated with Nerandomilast

100 Patents (Medical) associated with Nerandomilast

Literatures (Medical) associated with Nerandomilast

01 Jan 2026·Annals of Medicine and Surgery

Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis

Author: Hujjat, Syeda Fadak Zahra ; Chandani, Devya Khaim ; Khan, Muhammad Saad ; Chandani, Harshika Khaim ; Mahmoud, Abubakr

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with poor prognosis and limited therapeutic options. Despite the introduction of pirfenidone and nintedanib, treatment discontinuation due to adverse effects remains common, highlighting the need for better-tolerated, mechanistically distinct agents. Jascayd (nerandomilast), a first-in-class selective phosphodiesterase-4B inhibitor developed by Boehringer Ingelheim, was approved by the FDA in October 2025 for adults with IPF. By elevating intracellular cyclic adenosine monophosphate (cAMP) in inflammatory and structural lung cells, nerandomilast suppresses pro-inflammatory cytokines and fibroblast activation, producing anti-inflammatory and antifibrotic effects with improved tolerability over nonselective PDE4 inhibitors. In phase 3 FIBRONEER-IPF and FIBRONEER-ILD trials, nerandomilast significantly reduced the annual rate of forced vital capacity decline versus placebo, regardless of concomitant antifibrotic use. Common adverse effects included mild diarrhea, nausea, and fatigue, with low discontinuation rates. Long-term extension data demonstrate sustained safety and lung function preservation. Offering both monotherapy and combination potential, Jascayd establishes a new therapeutic class that targets inflammation and fibrosis concurrently, representing a pivotal advancement toward personalized, multi-pathway treatment in IPF.

01 Jan 2026·TRENDS IN PHARMACOLOGICAL SCIENCES

Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis

Article

Author: Ibrahim, Md ; Piazza, Gary A ; Ahsan, Fakhrul

01 Nov 2025·AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Insights into the Cellular and Molecular Mechanisms behind the Antifibrotic Effects of Nerandomilast

Article

Author: Herrmann, Franziska E. ; Geillinger-Kästle, Kerstin ; Wolf, Felix ; Mayr, Christoph H. ; Reininger, Dennis ; Wespel, Susanne L. ; Dick, Alec ; Laufhaeger, Nadine ; Gantner, Florian ; Nickolaus, Peter

The quest for innovative pharmacologic interventions in idiopathic pulmonary fibrosis (IPF) is a challenging journey. The complexity of the disease demands a comprehensive approach that targets multiple cell types and pathways. This study examined the antifibrotic properties of nerandomilast, a preferential phosphodiesterase 4B inhibitor, focusing on its effects on myofibroblasts (MFs) and endothelial cells. Using cytokine-stimulated human IPF lung fibroblasts and RNA sequencing, we assessed the effects of nerandomilast on MF contractility, MF markers, and differentiation mechanisms. In addition, using human microvascular endothelial cells, we assessed endothelial barrier integrity and monocyte adhesion in a three-dimensional microfluidic chip. Our results show that nerandomilast significantly inhibited MF contractility and marker expression in cytokine-stimulated human IPF lung fibroblast cells. Treatment with nerandomilast significantly activated cAMP-associated pathways and G-protein-coupled receptor signaling events while inhibiting mitogen-activated protein kinase signaling pathways and transforming growth factor β signaling. Nerandomilast also significantly reduced microvascular permeability in cytokine-stimulated human lung microvascular endothelial cells. Finally, in an adeno-associated virus-human diphtheria toxin receptor/diphtheria toxin mouse model of acute lung injury, nerandomilast significantly inhibited total protein in lavage, total macrophages, neutrophils, cell count, and VCAM-1 expression. In summary, our results demonstrate that nerandomilast induces the dedifferentiation of human IPF lung MFs and diminishes their contractility in vitro by interfering with transforming growth factor β, mitogen-activated protein kinase phosphatase-1, and G-protein-coupled receptor signaling pathways. It also mitigates vascular dysfunction by strengthening endothelial junctions and inhibiting adhesion protein expression. These findings highlight nerandomilast's potential therapeutic use in IPF by providing insights into its cellular and molecular actions.

News (Medical) associated with Nerandomilast

20 Jan 2026

·www.prnewswire.com

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan (HRCT) imaging biomarkers as a co-primary endpoint OXFORD, England and CHICAGO, Jan. 20, 2026 /PRNewswire/ -- Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced it was selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD), to provide objective, quantitative HRCT imaging biomarkers as a co-primary endpoint in the DROP-FPF Phase 3 study. Continue Reading Brainomix e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically quantifies and segments CT lung scans. DROP-FPF is a Phase 3b double blind, randomized, placebo-controlled study investigating the safety and effectiveness of nerandomilast (Jascayd®) in individuals with interstitial lung abnormalities (ILA's) and a family history of pulmonary fibrosis. Jascayd® received FDA approval for both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) in late 2025, ushering in a new therapeutic option to help manage these devastating forms of ILD. The study, set to initiate patient enrollment in January and include a two-year follow-up period, will investigate whether early intervention with nerandomilast slows the progression of early signs of pulmonary fibrosis in people with a family history of the condition. Pulmonary fibrosis causes irreversible lung damage and impacts 3-4 million people worldwide1. Yet individuals at elevated risk due to family history currently have no approved treatment options until symptoms emerge, often after substantial lung damage has already occurred. This trial marks the first time that automated, quantitative high-resolution CT (HRCT) imaging biomarkers will serve as a co-primary endpoint in a Phase 3 ILD study. Brainomix's AI-powered e-Lung software will provide objective measurements of fibrosis extent and disease severity by analyzing HRCT scans at baseline and at follow-up timepoints. Martin Beck, Senior VP and Head of Therapeutic Area Inflammation at Boehringer Ingelheim, commented: "IPF and PPF are serious, progressive lung diseases that can be more life-threatening than some forms of cancer. They progress silently, with early symptoms often dismissed as ageing or misdiagnosed. But in a progressive disease, there is no going back. Once fibrosis advances, the damage is irreversible. That's why this study is so important. Our goal is simple but profound: learn whether acting earlier can change outcomes for families facing these devastating diseases. Using Brainomix's advanced HRCT algorithms to define meaningful progression, we aim to generate insights that could transform how and when to intervene." Professor Peter George, Consultant Pulmonologist at the Royal Brompton Hospital, UK and Brainomix Senior Medical Director, added: "Accurate and reliable quantification of subtle but clinically meaningful features of disease progression is essential to achieving the objectives of this study. Brainomix e-Lung enables this through validated, proprietary, AI-driven CT biomarkers that accurately quantify physiologically meaningful features of interstitial lung disease. This information can reveal whether disease biology is changing, even when patients still appear clinically well and have normal lung function, allowing researchers to detect treatment effects far earlier than previously possible. This has the potential to significantly improve clinical trial design." The AI-powered and FDA-cleared e-Lung software has been trained on large, diverse datasets of patients with various forms of ILD and has been validated in the Phase 3 INBUILD study that originally led to the approval of nintedanib (Ofev®) in patients with progressive pulmonary fibrosis. The DROP-FPF study will be delivered in partnership with Voiant – the industry leading AI-based clinical trial imaging solution provider – leveraging Brainomix's advanced imaging biomarkers alongside Voiant's centralized image management and analytics framework. "AI-driven quantitative imaging analysis enables more confident detection of treatment effects while improving efficiency through smarter patient selection and optimized trial design. By combining Brainomix's advanced imaging biomarkers with Voiant's independent imaging and analytics framework, the study will deliver higher-precision respiratory endpoints with greater speed and reliability," Jessica Ataharul, Vice President of Clinical Operations at Voiant. 1. Boehringer Ingelheim, Facts about IPF – Respiratory Disease About Brainomix Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung fibrosis. Its flagship product, Brainomix 360 Stroke, is the world's first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung technology applies AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis. Founded as a spinout from the University of Oxford, Brainomix has offices in the UK, Ireland and the USA, and operations in more than 20 countries. To learn more about Brainomix and its technology visit , and follow us on Twitter, LinkedIn, and Facebook. Contacts Jeff Wyrtzen, Chief Marketing Officer [email protected] T +44 (0)1865 582730 Media Enquiries Jason Braco, Ph.D. LifeSci Communications [email protected] UK & Europe Media Enquiries Sue Charles Charles Consultants [email protected] Photo - Logo - SOURCE Brainomix 21% more press release views with Request a Demo

Phase 3

20 Jan 2026

·firstwordpharma.com

Brainomix AI imaging takes centre stage in Boehringer Ingelheim lung disease trial

Medicine rarely gets a second chance with pulmonary fibrosis, a silent disease often discovered only after irreversible damage has set in. But Boehringer Ingelheim is now testing whether earlier treatment, tracked using AI-powered CT scans, can finally put doctors ahead of the disease instead of chasing it.The DROP-FPF study – the first time that automated, quantitative high-resolution CT (HRCT) imaging biomarkers will serve as a co-primary endpoint in a Phase III interstitial lung disease (ILD) trial – will incorporate imaging analysis from Brainomix's e-Lung software alongside conventional measures to assess disease progression. The move reflects a shift in how late-stage pulmonary fibrosis trials define meaningful change, with imaging taking on a role traditionally held by clinical and functional endpoints (see – Spotlight On: What Boehringer Ingelheim's AI imaging endpoint bet signals for pharma).DROP-FPF is evaluating Boehringer's Jascayd (nerandomilast) in people with interstitial lung abnormalities who have a family history of pulmonary fibrosis. Unlike previous late-stage studies that enrolled patients with established idiopathic or progressive pulmonary fibrosis, the trial is focused on earlier disease, when changes can already be seen on CT scans, even though patients may have few symptoms.It will compare CT scans taken at baseline and during follow-up, using Brainomix's e-Lung software to measure changes in fibrosis and overall disease severity. Those imaging results will be assessed alongside lung function tests, which can be slow to change.In 2024, Brainomix reported data showing that its automated CT biomarkers could identify patients with idiopathic pulmonary fibrosis who were more likely to experience lung function decline based on a single baseline scan. The findings, drawn from a discontinued AstraZeneca trial and published in the American Journal of Respiratory and Critical Care Medicine, showed the imaging could distinguish patients with faster-progressing disease from those with more stable patterns.Jascayd recently secured expanded US approval for progressive pulmonary fibrosis, following Phase III data showing a smaller decline in forced vital capacity than placebo.Boehringer said the DROP-FPF trial is intended to assess whether intervening earlier can alter disease trajectory in people at elevated risk, using imaging to define meaningful change in a condition that can progress silently.The study is expected to begin enrolling patients in January and will follow participants for two years. Imaging delivery and analysis will be supported by Voiant, which is providing centralised image management and analytics for the trial.

Phase 3

13 Jan 2026

·www.biospace.com

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis (IPF) Ingelheim, Germany, 13 January 2026 – Boehringer Ingelheim today announced the start of a Phase IIa clinical trial evaluating BI 765423 , a novel monoclonal antibody targeting interleukin-11 (IL-11), in patients with idiopathic pulmonary fibrosis (IPF). This study marks a significant milestone in the company’s commitment to advancing care for people living with progressive fibrotic lung diseases. IPF is a progressive, life-shortening lung disease that affects over three million people worldwide and most patients experience worsening breathlessness and declining lung function. It is deadlier than many forms of cancer, with a lower five-year survival rate compared to prostate cancer, female breast cancer and colon cancer. IPF substantially impacts quality of life and half of patients succumb to the disease within five years of diagnosis. Current medicines can slow disease progression but cannot fully halt lung function decline or reverse lung scarring. There remains a high unmet need for stopping disease progression or reversing the effects of IPF. “With BI 765423, we aim to go beyond slowing disease and to pursue next generation therapies that could restore lung functionality for people living with IPF,” said Vittoria Zinzalla, Global Head of Experimental Medicine at Boehringer Ingelheim. “Our aim is to transform the lives of patients and their families by demonstrating the potential of this first-in-class IL-11 inhibitor to deliver clear benefits for patients, backed by compelling evidence and delivered at speed. “ IL-11 plays a key role in fibrosis across multiple organs, and pre-clinical studies have shown that anti-IL-11 treatment can halt fibrosis and restore barrier function, resulting in improved lung function and tissue integrity. BI 765423 is designed to bind directly to IL-11, blocking its interaction with its receptor and thereby interrupting the signaling pathways that cause fibrosis. By targeting this mechanism, BI 765423 aims not only to slow lung damage but also to help restore lung functionality. In Phase I studies, BI 765423 showed a favorable safety and tolerability pro healthy volunteers across a wide dose range. The Phase IIa study will be the first to evaluate its efficacy in patients with IPF. It is an acquired asset from Enleofen with in-licensed IP from Singapore Health Services and the National University of Singapore. Boehringer Ingelheim has a long-standing commitment to advancing care in pulmonary fibrosis and was just granted FDA approval for JASCAYD®, the first new treatment option in IPF in a decade. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at . Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Phase 1Phase 2Drug ApprovalClinical Result

100 Deals associated with Nerandomilast

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Progressive pulmonary fibrosis	China	Boehringer Ingelheim International GmbH	09 Dec 2025
Idiopathic Pulmonary Fibrosis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	07 Oct 2025
Idiopathic Pulmonary Fibrosis	United States	Boehringer Ingelheim Norway KS	07 Oct 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic Interstitial Pneumonias	Phase 3	United States	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Japan	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Argentina	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Belgium	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Canada	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	France	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Germany	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Italy	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Netherlands	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	South Korea	Boehringer Ingelheim GmbH	23 Jan 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05321082 (FIBRONEER-ILD, CTgov)	Phase 3	Progressive fibrotic interstitial lung disease	1,178	Placebo (Placebo)	yymbwqfnje(zjwlsdkhxn) = klgbmhxdjh hjmfvgvcyf (pmnisnjybz, wmfzmkrbxy - gmmyisdnwx) View more	-	09 Jan 2026
				BI 1015550 (Nerandomilast 9 mg)	yymbwqfnje(zjwlsdkhxn) = rmbyimmbcv hjmfvgvcyf (pmnisnjybz, chlnmfouip - rcodiujfyt) View more
NCT06624072 (CTgov)	Phase 1	-	15	Nerandomilast (Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1))	fsxtjdvgzv(yldzsxshpj) = lwqkegyknt fpixkjfnvh (uvpmfxowoc, NA) View more	-	08 Jan 2026
				Nerandomilast (Nerandomilast 18 mg Adult Fasted State (Reference R))	fsxtjdvgzv(yldzsxshpj) = soowssxjbu fpixkjfnvh (uvpmfxowoc, NA) View more
NCT06070610 (CTgov)	Phase 1	-	14	Pirfenidone+Nintedanib (Pirfenidone/Nintedanib alone (Reference))	nibbpavsgu(whlmpvibso) = nmxsaszpbq lqkhyndkrp (kzgsgpvcdt, NA) View more	-	02 Dec 2025
				Pirfenidone+Nerandomilast+Nintedanib (Pirfenidone/Nintedanib in combination with Nerandomilast (Test))	nibbpavsgu(whlmpvibso) = diubkwkqgb lqkhyndkrp (kzgsgpvcdt, NA) View more
NCT06393127 (CTgov)	Phase 1	-	64	nerandomilast (Test treatment (T))	fawalqdhae(lnhccwcbjf) = kwhchccwtw qejrvfrsiv (nsfarjwlzj, NA) View more	-	01 Dec 2025
				nerandomilast (Reference treatment (R))	fawalqdhae(lnhccwcbjf) = vhinnldkqy qejrvfrsiv (nsfarjwlzj, NA) View more
NCT05550636 (CTgov)	Phase 1	-	15	Midazolam (Midazolam (R))	covxbcnhxz(nlrlzijdhi) = obrwrgeatp uqeiczyswl (hhciaoztqt, NA) View more	-	01 Dec 2025
				Midazolam (T+BI 1015550 (BI 1015550 + Midazolam (T))	covxbcnhxz(nlrlzijdhi) = byemxqkxaj uqeiczyswl (hhciaoztqt, NA) View more
NCT06408870 (CTgov)	Phase 1	-	64	BI 1015550 (BI 1015550 Formulation C1 (Reference, R))	fkhqklrddj(spinlkvmmw) = xdspuoqrxn luumequmxa (onreprrhxc, na) View more	-	01 Dec 2025
				BI 1015550 (BI 1015550 Formulation C2 (Test, T))	fkhqklrddj(spinlkvmmw) = ikqrnpnajj luumequmxa (onreprrhxc, na) View more
NCT06415045 (CTgov)	Phase 1	-	18	Nerandomilast (Nerandomilast fasted state (Reference (R)))	ppyakfltnt(goyszhqsxt) = fpqddptqsc riyrcigqgh (ehtiqoefts, NA) View more	-	01 Dec 2025
				Nerandomilast (Nerandomilast fed state (Test (T)))	ppyakfltnt(goyszhqsxt) = ezrcqyyrkc riyrcigqgh (ehtiqoefts, NA) View more
NCT06139302 (CTgov)	Phase 1	-	12	Nerandomilast (Nerandomilast 9 mg)	smdgommpnu(lfyseirico) = gllevauuuc dndfdvicjr (zfcskigzab, 13.8) View more	-	01 Dec 2025
				Nerandomilast (Nerandomilast 18 mg)	smdgommpnu(lfyseirico) = ehglxekfdf dndfdvicjr (zfcskigzab, 52.8) View more
NCT05718648 (CTgov)	Phase 1	Renal Insufficiency	26	BI 1015550 (BI 1015550 Severe renal impairment)	ckodsnnbkz(odwkmwuxgx) = fjkbxymtga nfixbghwuj (xdmviiulaz, NA) View more	-	28 Nov 2025
				BI 1015550 (BI 1015550 Moderate renal impairment)	ckodsnnbkz(odwkmwuxgx) = dgbgqdmurh nfixbghwuj (xdmviiulaz, NA) View more
NCT03230487 (CTgov)	Phase 1	-	42	Placebo Single Dose (SD) (Placebo Single Dose (SD))	acqljptwsu = ytnzrkxxxt exjhrggulh (tknqgqmioc, enbcyoibvm - wzdwrkxxma) View more	-	28 Nov 2025
				Placebo (Placebo Multiple Dose (MD))	acqljptwsu = zuvftytvet exjhrggulh (tknqgqmioc, zostcntuoz - avlcwfgfut) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nerandomilast

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation